Evaluation of Histone Deacetylase Inhibitors as Therapeutics for Neurodegenerative Diseases

Methods in Molecular Biology

Volumn 793, Issue , 2011, Pages 495-508

  Soragni, Elisabetta ^a   Xu, Chunping ^a   Cooper, Andrew ^b   Plasterer, Heather L ^b   Rusche, James R ^b   Gottesfeld, Joel M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b REPLIGEN CORPORATION   (United States)

Author keywords

Chromatin immunoprecipitation; Epigenetics; Friedreich s ataxia; Gene activation; Histone deacetylase; Huntington s disease; Pimelic o aminobenzamide HDAC inhibitor; qRT PCR

Indexed keywords

FRATAXIN; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IRON BINDING PROTEIN; MESSENGER RNA;

ACETYLATION; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL SEPARATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; DRUG SCREENING; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; HUNTINGTON CHOREA; LABORATORY; MALE; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACETYLATION; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CELL SEPARATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DRUG EVALUATION, PRECLINICAL; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HUNTINGTON DISEASE; IRON-BINDING PROTEINS; LABORATORIES; LEUKOCYTES, MONONUCLEAR; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80054735825     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-328-8_32     Document Type: Chapter

References (8)

1. Marks, P., and Breslow, R. (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25, 84–90
2. Kazantsev, A. G., and Thompson, L. M. (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854–868.
3. Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., and Gottesfeld, J. M. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nature Chem. Biol. 2, 551–558.
4. Rai, M., Soragni, E., Chou, C. J., Barnes, G., Jones, S., Rusche, J. R., Gottesfeld, J. M., and Pandolfo, M. (2010) Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich’s ataxia patients and in a mouse model. PLoS One 5, e8825.
5. Rai, M., Soragni, E., Jenssen, K., Burnett, R., Herman, D., Gottesfeld, J. M., and Pandolfo, M. (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3, e1958 doi:1910.1371/journal. pone.0001958.
6. Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., Geschwind, D. H., and Gottesfeld, J. M. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington’s disease transgenic mice. Proc. Natl. Acad. Sci. USA 105, 15564–15569.
7. Chou, C. J., Herman, D., and Gottesfeld, J. M. (2008) Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. 283, 35402–35409.
8. Xu, C., Soragni, E., Chou, C. J., Herman, D., Plasterer, H. L., Rusche, J. R., and Gottesfeld, J. M. (2009) Chemical probes identify a role for histone deacetylase 3 in Friedreich’s ataxia gene silencing. Chem. Biol. 16, 980–989.